Related Experiment Video
Updated: Jul 10, 2025

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects
John D Mably1,2,3, Da-Zhi Wang4,5,6,7
1Center for Regenerative Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Abstract:
The surge in reports describing non-coding RNAs (ncRNAs) has focused attention on their possible biological roles and effects on development and disease. ncRNAs have been touted as previously uncharacterized regulators of gene expression and cellular processes, possibly working to fine-tune these functions. The sheer number of ncRNAs identified has outpaced the capacity to characterize each molecule thoroughly and to reliably establish its clinical relevance; it has, nonetheless, created excitement about their potential as molecular targets for novel therapeutic approaches to treat human disease. In this Review, we focus on one category of ncRNAs - long non-coding RNAs - and their expression, functions and molecular mechanisms in cardiac hypertrophy and heart failure. We further discuss the prospects for this specific class of ncRNAs as novel targets for the diagnosis and treatment of these conditions.
Related Concept Videos
Pathophysiology of Heart Failure
lncRNA - Long Non-coding RNAs
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pathophysiology of Cardiac Performance
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

